Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.76 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.65 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17685050 | 0.99 | CHEK1 (0.75) | CHEK1RPS6KB1FLT4FLT3RPS6KA3 | |
| SCHEMBL16207253 | 0.86 | CHEK1 (1.00) | CHEK1RPS6KB1FLT4FLT3RPS6KA3 | |
| Hydrochloric Acid SCHEMBL17685145 | 0.86 | CHEK1 (0.98) | CHEK1RPS6KB1FLT4FLT3RPS6KA3 | |
| SCHEMBL16206658 | 0.85 | CHEK1 (1.00) | CHEK1 | |
| Hydrochloric Acid SCHEMBL17684920 | 0.84 | CHEK1 (0.98) | CHEK1 | |
| SCHEMBL16206651 | 0.82 | CHEK1 (1.00) | CHEK1RPS6KB1FLT4FLT3RPS6KA3 | |
| SCHEMBL18780355 | 0.82 | CHEK1 (0.76) | CHEK1FLT4FLT3RPS6KA3PRKD2 | |
| Hydrochloric Acid SCHEMBL17684907 | 0.81 | CHEK1 (0.98) | CHEK1RPS6KB1FLT4FLT3RPS6KA3 | |
| SCHEMBL16206643 | 0.80 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL14965537 | 0.79 | CHEK1 (1.00) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | PHKG1, PHKG2, PLK2 | CHEK1 36/4885RPS6KB1 269/4885FLT4 1232/4885 |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | PHKG1, PHKG2, PEAK1 | CHEK1 29/4885RPS6KB1 277/4885FLT4 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.